Relationships of dermatologic symptoms and quality of life in patients with psoriatic arthritis: analysis of two tofacitinib phase III studies by Peter C. Taylor, Andrew G. Bushmakin, Joseph C. Cappelleri, Pamela Young, Rebecca Germino, Joseph F. Merola, Gil Yosipovitch

“…Objectives Evaluate relationships between changes in dermatologic assessments and quality of life (QoL) measures; quantify dermatologic symptom severity impacts on QoL in patients with psoriatic arthritis (PsA) treated with tofacitinib.Methods Data were from two phase III studies; patients received tofacitinib 5 or 10 mg twice daily (BID), adalimumab 40 mg every other week, or placebo advancing to tofacitinib 5 or 10 mg BID at Month 3. …”
Get full text

Patient Characteristics, Diagnoses, and Management in a Combined Uveitis–Rheumatology Clinic by Jason Shawver, Amit K. Reddy, Alan G. Palestine, Jason R. Kolfenbach

“…The most common systemic immunomodulatory therapies (IMT) used were adalimumab, methotrexate, and rituximab. Over 40% of patients underwent a change in IMT during their first evaluation. …”
Get full text

A Network Meta-Analysis to Compare Effectiveness of Baricitinib and Other Treatments in Rheumatoid Arthritis Patients with Inadequate Response to Methotrexate by Walid Fakhouri, Xiaofei Wang, Inmaculada de La Torre, Claudia Nicolay

“…For ACR20, BARI 4 mg + MTX was found to be more effective than adalimumab (ADA) 40 mg + MTX (Odds Ratio [OR] 1.33), abatacept (ABA) 10 mg + MTX (IV/4 weeks) (OR 1.45), infliximab (IFX) 3 mg + MTX (IV/8 wks) (OR 1.63), and rituximab (RTX) 1000 mg + MTX (OR 1.63). …”
Get full text

The Association of TNF-Alpha Inhibitors and Development of IgA Nephropathy in Patients with Rheumatoid Arthritis and Diabetes by Vedran Premužić, Ivan Padjen, Mislav Cerovec, Marijana Ćorić, Bojan Jelaković, Branimir Anić

“…Two patients were treated with adalimumab while one patient was treated with golimumab. …”
Get full text

Evaluating Meaningful Changes in Patient‐Reported Outcome Measurement Information System–Fatigue Scores from Three Phase 3 Clinical Trials of Sarilumab for Patients With Rheumatoid... by Clifton O. Bingham, Emily Molina, Amy Praestgaard, Stefano Fiore, David Cella

“…When compared to patients who received adalimumab in MONARCH, patients who received sarilumab had a trend toward increased improvement. eCDF curves showed separation between active treatment versus placebo with both sarilumab doses and across the score range for improvement. …”
Get full text

Relationship Between Patient Demographics and Biologic Therapy Use in Inflammatory Bowel Disease. A Single Center Cross‐Sectional Study by Mohammad Shehab, Abdulwahab Alsayegh, Munirah Alabdulhadi, Shahed Snober, Nouf Aleissa, Ahmad Alfadhli

“…Results Among the 513 patients using biologic therapy in this study, there were 210 (40.9%) on adalimumab (ADL), 154 (30.0%) on infliximab (IFX), 112 (21.9%) on ustekinumab (UST), and 33 (6.4%) on vedolizumab (VDZ). …”
Get full text

Reduction of depressive symptoms among patients with inflammatory bowel disease treated with biological therapy: a quantitative comparative incision study by J. Zinkevičiūtė, S. Ambrasas, A. Kiziela, R. Strumila, S. Brašiškienė, E. Dlugauskas

“…To compare depression and anxiety symptoms between the patients with inflammatory bowel disease receiving tumor necrosis factor-alpha (TNF-α) inhibitor (adalimumab, infliximab) and the patients receiving different medical treatment. …”
Get full text

The Uncoupling of Disease Activity from Joint Structural Progression in Patients with Rheumatoid Arthritis Treated with Filgotinib by Yoshiya Tanaka, Tatsuya Atsumi, Daniel Aletaha, Hendrik Schulze-Koops, Haruhiko Fukada, Chris Watson, Tsutomu Takeuchi

“…Methods Patients with RA and inadequate response to methotrexate (MTX) use were randomized 3:3:2:3 to FIL 200 mg (FIL200) or FIL 100 mg (FIL100) once daily, adalimumab 40 mg biweekly, or placebo, all with background MTX. …”
Get full text

Management of Inflammatory Bowel Disease during Pregnancy and Breastfeeding Varies Widely: A Need for Further Education by Vivian Wai-Mei Huang, Hsiu-Ju Chang, Karen Ivy Kroeker, Karen Jean Goodman, Kathleen M. Hegadoren, Levinus Albert Dieleman, Richard Neil Fedorak

“…For specified IBD medications, proportions of physicians who indicated they would continue them during pregnancy were as follows: sulfasalazine, 47.4%; oral mesalamine, 67.0%; topical mesalamine, 70.3%; oral prednisone, 68.0%; topical prednisone, 78.0%; oral budesonide, 61.6%; topical budesonide, 75.0%; ciprofloxacin, 15.3%; metronidazole, 31.4%; azathioprine, 57.1%; methotrexate, 2.8%; infliximab, 55.6%; adalimumab, 78.1%. Similar proportions of physicians would continue these medications during breastfeeding. …”
Get full text

Anti-Tumor Necrosis Factor-α Use in Pediatric Inflammatory Bowel Disease—Reports from a Romanian Center by Roxana Matran, Andra-Mihaela Diaconu, Andreea Maria Iordache, Irina Dijmărescu, Alexandra Coroleucă, Daniela Păcurar, Cristina Becheanu

“…<b>Background/Objectives:</b> The introduction of anti-tumor necrosis factor-α (anti-TNF-α) agents, particularly infliximab (IFX) and adalimumab (ADA), has significantly expanded the therapeutic arsenal for inflammatory bowel disease (IBD). …”
Get full text

UNEXPECTED FINDINGS DURING LAPAROTOMY SURGERY AND URGENT SURGICAL INDICATIONS ARE ASSOCIATED WITH POSTOPERATIVE COMPLICATIONS IN PATIENTS WITH CROHN’S DISEASE by Guilherme Zupo TEIXEIRA, Magaly Gemio TEIXEIRA, Marina Carla GIMENEZ, Silvia Caroline Neves RIBEIRO, Nathacia Bernardo CHIMELLO, Vania Aparecida LEANDRO-MERHI

“…RESULTS: There was an association regarding the history of adalimumab use (p=0.04, OR 2.8, 95%CI 1.03-7.65), previous use of prednisone (p<0.01, OR 2.03, 95%CI 2.00-2.05), urgent surgery indications (p<0.01, OR=4.32, 95% CI=1.58-11.82), mechanical anastomosis (p=0.02, OR=0.22, 95%CI 0.06-0.80), unexpected intraoperative findings (p=0.02, OR 10.46, 95%CI 1.50-72.99), length of hospital stay greater than 10 days (p<0.01, OR 16.86, 95%CI 2.99-94.96), unplanned intensive care unit (ICU) admission (p=0.01, OR 15.06, 95%CI 1.96-115.70), and planned ICU admission (p<0.01, OR 18.46, 95%CI 3.60-94.51). …”
Get full text

Real-World Health Care Outcomes and Costs Among Patients With Juvenile Idiopathic Arthritis in Spain by Jordi Antón, Estefania Moreno Ruzafa, Mireia Lopez Corbeto, Rosa Bou, Judith Sánchez Manubens, Sonia Carriquí Arenas, Joan Calzada Hernández, Violetta Bittermann, Carolina Estepa Guillén, Juan Mosquera Angarita, Lucía Rodríguez Díez, Estíbaliz Iglesias, Miguel Marti Masanet, Berta Lopez Montesinos, Maria I. González Fernández, Alfonso de Lossada, Carmen Peral, Mónica Valderrama, Noelia Llevat, María Montoro Álvarez, Immaculada Calvo Penadés

“…Among anti-TNFα treatments, adalimumab (47.4%) and etanercept (40.2%) were used in similar proportions. …”
Get full text

Evaluation of Treatment Patterns and Maintenance Dose Titration Among Patients With Crohn’s Disease Initiating Biologics With 3 Years of Follow-Up by Ruizhi Zhao, Zhijie Ding, Parul Gupta, Laurence Gozalo, Robert Bruette, Victor M. Johnson, Keshia Maughn, Yihang Liu, Sumesh Kachroo

“…Adult patients with at least 1 CD medical claim and at least 1 medical/pharmacy claim for a biologic (adalimumab \[ADA\], certolizumab pegol (CZP), infliximab \[IFX\] and its biosimilar products \[IFX-BS\], ustekinumab \[UST\], and vedolizumab \[VDZ\]) between September 2016 and October 2018 were identified. …”
Get full text

Onychomycosis in Psoriatic Patients with Nail Disorders: Aetiological Agents and Immunosuppressive Therapy by Núbia Carvalho Pena de Oliveira Praeiro Alves, Tomaz de Aquino Moreira, Lucivânia Duarte Silva Malvino, José Joaquim Rodrigues, Roberto Ranza, Lúcio Borges de Araújo, Reginaldo dos Santos Pedroso

“…Six patients (15.78%) were not using immunosuppressive therapy, and the others were using methotrexate, etanercept, adalimumab, infliximab, secukinumab, or golimumab, in monotherapy or in combination with other drugs. …”
Get full text

Biologic Therapy and Cardiometabolic Risk in Psoriasis: A Retrospective Review by Annika Smith, Aidin Karahasan, Deborah Yi, Sanjay Yapabandara, James Elhindi, Pablo Fernandez-Penas, Clara Chow, Sarah Zaman

“…The biologic agents used, according to frequency, included risankizumab, with 14 participants (35.9%), secukinumab by 7 (17.9%), ustekinumab by 6 (15.4%), ixekizumab by 6 (15.4%), guselkumab by 3 (7.7%), infliximab by 2 (5.1%), and adalimumab by 1 (2.6%). After 12 months, significant skin improvement was seen [PASI reduced from 13.43 (SD 9.8) to 1.1 (SD 2.1), p < 0.001]. …”
Get full text

Real-World Persistence and Effectiveness of Upadacitinib versus Other Janus Kinase Inhibitors and Tumor Necrosis Factor Inhibitors in Australian Patients with Rheumatoid Arthritis by Peter Youssef, Sabina Ciciriello, Talib Tahir, Joanna Leadbetter, Belinda Butcher, Miriam Calao, Nicole Walsh, Catherine O’Sullivan, Tegan Smith, Geoffrey Littlejohn

“…Patients initiated UPA (N = 2624), other JAKis (baricitinib and tofacitinib [N = 925]), or TNFis (adalimumab, etanercept, certolizumab, golimumab, infliximab [N = 3540]) between May 2020 and March 2023. …”
Get full text

Efficacy and Safety of Risankizumab in Patients with Psoriasis Showing Suboptimal Response to Secukinumab or Ixekizumab: Results from a Phase 3b, Open-Label, Single-Arm (aIMM) Stud... by Richard B. Warren, Lev Pavlovsky, Antonio Costanzo, Michael Bukhalo, Neil J. Korman, Yu-Huei Huang, Georgios Kokolakis, Andreas Pinter, Nadia Ibrahim, Yanbing Zheng, Leonidas Drogaris, Vassilis Stakias, Ahmed M. Soliman, Simone Rubant, Diamant Thaçi

“…Abstract Introduction Risankizumab has demonstrated superior efficacy compared to other psoriasis treatments, including secukinumab, adalimumab, and ustekinumab; switching to risankizumab from other psoriasis treatments has shown superior clinical and quality of life (QoL) outcomes. …”
Get full text